Lupus Trials News

The best and brightest are working toward finding better treatments and ultimately a cure for lupus. Read about how the most important influencers in the lupus community are effecting lupus research, along with other issues that matter most to you.

Study Finds Mycophenolate Mofetil Comparable to Standard Treatment for Pediatric Lupus Nephritis

March 19, 2019 A new study published in Lupus showed that mycophenolate mofetil (MMF) is comparable in effectiveness to the standard treatment intravenous cyclophosphamide (IVCYC) for lupus nephritis in pediatric patients. The study compared response to treatment, kidney damage, time needed to result in inactive lupus nephritis and disease flares. Of the 51 patients studied, […]

LRA-Supported Researchers Developed a Model to Predict Full-Blown Lupus Nephritis Down the Road

A new study funded by the Lupus Nephritis Trials Network with support from the Lupus Research Alliance has proposed a set of standardized measures that promise to improve the way clinical trials in lupus nephritis (LN) are structured and how clinical researchers report their results. The findings will also help researchers in their search for […]

Lupus Research Alliance and National Minority Quality Forum Release Recommendations to Advance New Lupus Treatments by Increasing Diversity in Clinical Trial Participation

NEW YORK, NY. March 14, 2019.  The Lupus Research Alliance (LRA) and the National Minority Quality Forum (NMQF) today released the insightful report, Addressing the Challenges of Clinical Research Participation Among Populations Disproportionately Impacted by Lupus. The report presents findings and actionable recommendations ranging in scope that can be implemented by any individual or group seeking […]

Lupus Therapeutics Partners with Takeda to Test Potential Treatment for Lupus

New York, NY– March 1.  The Lupus Research Alliance and its affiliate, Lupus Therapeutics announced a collaboration with Takeda Pharmaceutical Company Limited, to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916).  The national study will be conducted in 20 research centers throughout the country, many […]

Lupus Research Alliance Congratulates NIH on 5-Year AMP Success

February 28, 2019 NEW YORK, NY. As a co-sponsor of the National Institutes of Health (NIH) public-private Accelerating Medicines Partnership (AMP), the Lupus Research Alliance is proud to share the project’s five-year achievements reported in Nature Reviews Drug Discovery.  In the article, NIH Director Dr. Francis Collins points to new technology standards AMP created for […]

Bacteria in the Gut May be a Cause of Lupus and Flares: Shows Study Supported by Lupus Research Alliance

NEW YORK, NY. February 19. Pieces of bacteria that escape from the intestines may trigger lupus and associated disease flares in some patients, according to a new study partly funded by the Lupus Research Alliance. These findings may allow disease treatment with probiotics or diets that alter the mix of bacterial species in the intestines. […]

Stelara® and Olumiant® Considered Promising by Lupus Expert

February 19, 2019 In Healio Rheumatology, Dr. Gregg Silverman, professor of medicine and pathology at NYU School of Medicine, provided an overview of potential lupus therapies in development.  He highlighted ustekinumab (brand name Stelara®) and baricitinib (brand name Olumiant®) as two drugs that look particularly promising. “The phase 2 extra-renal trial of baricitinib looks good; […]

New Approach to Treating Lupus Nephritis

February 6, 2019 Scientists partly funded by the Lupus Research Alliance have found a potential new way to protect the kidneys in patients with lupus. A study led by Dr. Vicki Rubin Kelley of Brigham and Women’s Hospital in Boston, Massachusetts, suggests that blocking a molecule made by some cells in the kidney could reduce […]

Protein Osteopontin Indicator of Lupus Nephritis, Shows Clinical Trial

February 1, 2019 Raised levels of a protein osteopontin were shown to indicate lupus nephritis and higher disease activity, in a new study conducted at 33 centers by top lupus researchers worldwide. Published in The Journal of Rheumatology, the study looked at results from 344 lupus patients. At the beginning of the study (baseline), patients […]

Lupus Therapeutics Launches Peer Training Program to Help Patients Benefit from Clinical Trials

February 1, 2019 Today, Lupus Therapeutics, an affiliate of Lupus Research Alliance, is launching our Patient Advocates for Lupus Studies (PALS) program with a pilot study to determine its effectiveness in increasing awareness of and participation in lupus clinical trials, particularly among diverse populations.  The program will pair people with lupus interested in learning about […]

Lupus Research Alliance and Lupus Therapeutics Partner on New Phase 3 Trial Testing Potential Benefit of Ustekinumab (Stelara®) in Lupus

February 1, 2019 The Lupus Research Alliance announced that its affiliate Lupus Therapeutics is working with the pharmaceutical company, Janssen, to help conduct a Phase 3 trial to evaluate whether their drug ustekinumab (Stelara®) may offer benefit to people with lupus.  Called LOTUS, the international study is being conducted in over 200 sites, 20 of […]

Lupus Research Alliance Announces Translational Research Grants to Speed Development of New Treatments

NEW YORK, NY – January 10.  Can “borrowed” drugs for treating other diseases protect the skin in patients with lupus? Can researchers coax the body to weed out harmful immune cells that drive tissue destruction in lupus? Those are just two of the innovative approaches for lupus therapies recognized by the Lupus Research Alliance with […]

Lupus Research Alliance Applauds FDA’s Fast Track Designation to Develop Baricitinib for Lupus

NEW YORK, NY. December 14. The Lupus Research Alliance is pleased to share good news about a potential new treatment for systemic lupus erythematosus (SLE).  Yesterday, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to baricitinib, which is being studied for the treatment of SLE. […]

Potential New Lupus Treatment Outperforms Hydroxychloroquine in Animal Study

November 28, 2018 Anti-malaria drugs such as hydroxychloroquine are common treatments for arthritis and heat rash in patients with lupus. A new study by Target Identification in Lupus grantee Keith Elkon, MD, of the University of Washington, Seattle, and colleagues suggests that a new drug they designed works better than the commonly prescribed hydroxychloroquine in […]

ACR|ARHP News on Potential New Lupus Treatments

October 25, 2018 The Lupus Research Alliance was on the ground at the American College of Rheumatology 2018 meeting to bring you the latest news in lupus research and translation.  Several clinical trials showed benefits of potential new treatments for helping people with lupus. Following are summaries of the stand-out results: Ustekinumab (Stelara®) A Phase 2 […]

Serving Under-served Lupus Communities

October 15, 2018 The Lupus Research Alliance’s Multi-cultural Outreach Task Force is out in full force to raise awareness among the African American communities, who face a higher risk of developing the disease, at health expos around the country, including the Essence Music Festival in New Orleans, LA this summer and Healthy Churches 2020 National […]

Lupus Patient-Focused Drug Development Meeting

The Lupus Research Alliance collaborated with the Lupus and Allied Diseases Association and the Lupus Foundation of America on a groundbreaking initiative in cooperation with the Food and Drug Administration’s (FDA) externally-led Patient-Focused Drug Development (PFDD) program. The well-attended meeting hosted by the three groups supplemented by a national survey of people with lupus resulted […]

Patient Involvement: The Next Critical Step

Certainly, advocacy is absolutely necessary to generate funding for the National Institutes of Health (NIH) and other federal organizations, as well as for groups that support and conduct lupus research. But patient involvement is also critical to opening pathways to discovery. “Just helping to raise money isn’t enough,” said Diane Gross, National Director of Advocacy and […]

Cancer Study Shows How Body’s Trash Pickup Fails in Lupus

October 4, 2018 Immune cells called macrophages that normally clear away the body’s trash don’t do their jobs in lupus. Now, a study of cancer partly funded by the Lupus Research Alliance may explain how these macrophages promote lupus. Douglas Green, PhD, of St. Jude Children’s Research Hospital in Memphis, Tennessee, and colleagues found that […]

Good News from Aurinia Pharmaceuticals for Lupus Nephritis

September 25, 2018 Congratulations to Aurinia Pharmaceuticals for completing patient enrollment in the AURORA Phase 3 clinical trial ahead of schedule.  The company reported in a press release issued today that due to high patient demand, the target number of patients was surpassed with 358 lupus nephritis (LN) patients enrolled in sites across 27 countries. […]

Better Survival Rates from Severe Lupus Nephritis

September 20, 2018 Significantly more people are surviving end-stage renal (kidney) disease caused by lupus nephritis according to a long-term analysis published in Arthritis & Rheumatology. The analysis of the national registry of 20,974 patients with end-stage renal disease (ESRD) during the years 1995 through  2014 found that mortality rates significantly declined.  In addition, among […]

Data Finds Smoking Raises, Drinking Can Decrease Lupus Risk

Data from a long-term Black Women’s Health Study of 59,000 Black women found that cigarette smoking raised the risk for lupus, but not significantly compared with those who had never smoked.  In contrast, the incidence of lupus was significantly lower among Black women who drank moderately which was defined as greater or equal to four […]

Lupus Research Alliance: Disappointed but Undaunted by Anifrolumab Results

September 4, 2018 The Lupus Research Alliance is disappointed with the results announced by AstraZeneca and MedImmune of the clinical trial testing the investigational drug anifrolumab for moderate to severe systemic lupus erythematosus (SLE).  However, the knowledge gained from further analyzing these data will be invaluable in fully understanding the effects of anifrolumab and designing […]

Battling Lupus with Krill: Phospholipid-rich krill oil a potential new relief option for lupus

August 28, 2018 NEW YORK, NY. Aker BioMarine and Lupus Research Alliance launch a new clinical study, investigating how phospholipid-rich krill oil can benefit people with lupus, with the aim to lessen the severity of symptoms associated with the disease. Affecting an estimated 5 million people worldwide, Systemic Lupus Erythematosus (SLE), better known as lupus, […]

Potential Treatment for Sun Damage Discovered with LRA Funding

August 16, 2018 Exposure to the sun is hard on everyone’s skin, causing cells to die. But skin cells are much more vulnerable in people with lupus.  That reaction is called photosensitivity. A team of scientists led by Theresa Lu, MD, PhD, at Hospital for Special Surgery (HSS) in New York may have discovered why. […]

End of content

No more pages to load